Parkinsons Flashcards

1
Q

What is the definition of Parkinson’s

A

A neurodegenerative, progressive disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is PD characterised by

A

Bradykinesia
Rigidity
Tremor
Postural instability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What percentage of people develop Parkinson’s Disease

A

At age 60: 1%
At age 80: 4%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What age range does early onset occur and what is it linked to

A

Ages 21-40

Genetic component links

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is Parkinsonism

A

A neurological syndrome characterised by tremor, bradykinesia and rigidity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What causes Parkinsonism

A

-Drugs: Antimycotics, Metoclopramide, TCA and MPTP (Toxin for dopamine neurons)
-Vascular disease
-Trauma
-Parkinson’s plus syndrome
-Multiple system atrophy
-Progressive supranuclear palsy
-Corticobasal degeneration
-Lewy-body dementia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Parkinsonism is not reversible. TRUE or FALSE

A

FALSE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the classic TRIAD that is used to diagnose

A

BRADYKINESIA / slowness
RIGIDITY / stiffness / increased tone
TREMOR / pill rolling / 4-6 Hz /resting
AND
Postural instability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the initial symptoms of Parkinson’s

A

-Persistent mild fatigue
-Handwriting becomes shaky
-Becoming unbalanced or have difficulty performing sit-to-stand
-Agitation, irritability , depression and anxiety
-Masked face

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

List the motor symptoms of Parkinson’s

A

-Hand tremors
-Rigidity/ resistance
-Spontaneous movement become slower
-Imbalance: Vulnerable to falls
- Tiled forward
- Head down

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

List some non motor symptoms

A

Depression
Emotional changes
Memory loss
Swallowing difficulties and Lewy bodies -> Dementia
Speech problems
Bladder/Bowel disorders
Excessive sweating
Sleep disturbances

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are Lewy bodies

A

Insoluble aggregates in neurons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe the pathology of PD

A

1- Degeneration of pigmented neurones in the pars compacta of the substantia nigra.
2- Lewy Bodies
3- Degeneration of brainstem nuclei

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are Lewy bodies composed of

A

Aggregates containing Alpha-synuclein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

In healthy humans what is Alpha-synuclein used for

A

To control NT release

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the neurobiological of the motor system

A

The Basal ganglia pathway is involved in regulating movement (Extrapyramidal motor system)

GABA cell increased activity due to death of Dopaminergic substantial nigra cells to the striatum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What brain regions are involved in non-motor symptoms and what happens to those regions

A

Cell death in the:

-Locus coeruleus degeneration
-Nucleus Basalis
-Enteric nervous system NT release

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What effect does cell death in the locus coeruleus have on non-motor symptoms

A

Emotional changed
Anxiety
Stress

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What effect does cell death in the Nucleus Basalis have on non-motor symptoms

A

Memory decline
Cognition decline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What effect does enteric nervous systems NT release degeneration have on non-motor symptoms

A

Constipation
Swallowing
Drooling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are the causes PD

A

Unknown
Genetic (AS)
Environmental factors- toxins such as MPTP
Oxidative stresses - Free radical dopamine are cytotoxic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

List the 4 types of pharmacotherapeutic strategies

A

peripheral dopa decarboxylase inhibitor
to increase the amount that is delivered to the brain

Reduces peripheral side effects

23
Q

Name 2 dopamine replacement medication and which type of dopa decarboxylase inhibitor that they contain

A

Co-Beneldopa: Benzerazide
Co-Careldopa: Carbidopa

24
Q

Side effects of L-DOPA

A

GI side effect
Cardiovascualr S/E
Postural hypotension
Behavioural
Abnormal involuntary movement (Dyskinesia)
On-Off symptoms

25
Q

List the some DA receptor modulators

A

Amantadine
Dopaminergic agonists

26
Q

Which adjuvant is given along side L-dopa and why

A

peripheral dopa decarboxylase inhibitor
to increase the amount that is delivered to the brain

Reduces peripheral side effects

27
Q

What is Amantadine

A

An Antiviral agent that has anti-parkinsonian activity

28
Q

What is the mechanism of action of Amantadine

A

Releases dopamine from intact dopamine terminal in the striatum

29
Q

List some dopamine receptor agonist (Dopaminergic agonists)

A

Bromocriptine
Pergolide
Pramipexole
Ropinirole
Apomorphine

30
Q

Which dopamine agonists bind to D2 receptors

A

Bromocriptine
Pergolide
Ropinirole

31
Q

Which dopamine agonists bind to D1 receptors

A

Pergolide

32
Q

Which dopamine agonists bind to D3 receptors

A

Pramipexole

33
Q

what are the benefits of pergolide

A

More effective than Bromocriptine so therefore a lowered dose of L-dopa

34
Q

Cautions associated with Pergolide

A

Valvular heart disease so is less favourable than newer agents

35
Q

List the benefits of Pramipexole

A

Effective as a monotherapy for mild PD
Effective as co-therapy with L-dopa in advanced PD
May reduce affective symptoms of PD
Potential Neuroprotective effect

36
Q

List the Benefits of Ropinirole

A

Effective as monotherapy in mild PD
Effective “smoothening” the response to L-dopa

37
Q

What form is Apomorphine administered

A

Subcutaneously

38
Q

What is Apomorphine used for

A

Advanced cases that are unresponsive to other therapies to refractory motor fluctuation

39
Q

What types of medication stops the breakdown DA

A

MAOI -Mono amine oxidase inhibitors
COMT- catechol-o-methyl transferase inhibitors

40
Q

How many types of MOAs are there and what do they metabolise

A

2 types
MAO-A: Metabolises NA and 5-HT
MOA-B: Metabolises DA

41
Q

List the 2 MOAIs used for PD

A

Selegiline
Rasagiline

42
Q

What is the mechanism of MAOI for PD

A
  • Binds irreversibly to MA0-B
  • Prevents the breakdown of DA and prolongs antiparkinsonian effect of L-dopa
  • Lower dose of L-dopa needed
43
Q

What are the disadvantages of selegiline

A

Does not have any therapeutic effects

44
Q

what is the benefit of Rasagiline over Selegiline

A

Rasagline is more potent

45
Q

List the name of come COMT inhibitors

A
  • Entacapone
  • Tolcapone
46
Q

What is the mechanism of COMT Inhibitors

A

Prolong the activity of of L-dopa by preventing peripheral breakdown.

47
Q

List the antimuscarinic drugs of PD

A

Benztropine
Orphenadrine

48
Q

How do anti-muscarinic drugs help with PD

A

In PD there is an overexcitation of cholinergic neurons

the antimuscarinic drugs will block cholinergic receptor

49
Q

In which cases are anti-muscarinic drugs used

A

When the PD is drug induced NOT primary PD

50
Q

What are some none medical treatments for PD

A

Brain Graphs

Stem cell therapy

Deep brain stimulation

51
Q

Why is administering Parkinson’s medication, on time vital

A

Because the therapeutic window for the drug reduces over time, the dose must be given so that the persons symptoms does not appear.

52
Q

What adjunct treatments to Levo-dopa

A

Dopamine agonist: Non ergot then ergot derived

MAO-B inhibitors

COMT inhibitors

Then if the above doesn’t work use Amantadine

53
Q

When should the dose of Dopamine agonist be reduced

A

When there are impulse disorders.